Drugs / Tociluzumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05463133 | Jul 2022 → Dec 2032 expected | chronic granulomatous disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tociluzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05463133 ↗ |
| Known as | tocilizumab | “Participants with a CRP of less than 100 mg/mL will be pretreated with a dose of tocilizumab, an anti-IL6 monoclonal antibody.” NCT05463133 ↗ |
| Action | Inhibit | “An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.” NCT05463133 ↗ |
| Modality | Monoclonal antibody | “an anti-IL6 monoclonal antibody” NCT05463133 ↗ |